Search research articles
Contact Us
Filters
Showing results (61-70 of 173) with videos related to
Page
of 18
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safety
Rebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study
Krishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
Cancer
|
January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer
David Mutch, Athina Voulgari, Xian Marissa Chen, et al.
Investigational New Drugs
|
August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Rebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, et al.
Future Oncology (London, England)
|
June 29, 2023
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer
Ana Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Journal of Gynecologic Oncology
|
May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses
Jung-Yun Lee, Ana Oaknin, Luis Manso, et al.
Advances in Therapy
|
September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
The Lancet. Oncology
|
February 2, 2015
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)
Richard T Penson, Helen Q Huang, Lari B Wenzel, et al.
Advances in Therapy
|
March 6, 2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 173) with videos related to
Sort By:
Page
of 18
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safety
Rebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study
Krishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
Cancer
|
January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer
David Mutch, Athina Voulgari, Xian Marissa Chen, et al.
Investigational New Drugs
|
August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Rebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, et al.
Future Oncology (London, England)
|
June 29, 2023
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer
Ana Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Journal of Gynecologic Oncology
|
May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses
Jung-Yun Lee, Ana Oaknin, Luis Manso, et al.
Advances in Therapy
|
September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
The Lancet. Oncology
|
February 2, 2015
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)
Richard T Penson, Helen Q Huang, Lari B Wenzel, et al.
Advances in Therapy
|
March 6, 2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Page
of 18